{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:23:34Z","timestamp":1793381014515,"version":"4.5.0"},"reference-count":222,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/mjt.0b013e3182456dff","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T13:13:15Z","timestamp":1359033195000},"page":"106-130","source":"Crossref","is-referenced-by-count":29,"title":["Painful Boney Metastases"],"prefix":"10.1097","volume":"21","author":[{"given":"Howard S.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Barkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-8-20210202","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0022-5347(05)67149-2","article-title":". Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.","volume":"164","author":"Berruti","year":"2000","journal-title":"J Urol"},{"key":"R3-8-20210202","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0304-3959(01)00324-4","article-title":". Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology.","volume":"93","author":"Meuser","year":"2001","journal-title":"Pain"},{"key":"R4-8-20210202","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","article-title":". Prevalence of pain in patients with cancer: a systematic review of the past 40 years.","volume":"18","author":"van den Beuken-van Everdingen","year":"2007","journal-title":"Ann Oncol"},{"key":"R5-8-20210202","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.pain.2007.08.022","article-title":". High prevalence of pain in patients with cancer in a large population-based study in The Netherlands.","volume":"132","author":"van den Beuken-van Everdingen","year":"2007","journal-title":"Pain"},{"key":"R6-8-20210202","first-page":"1451","article-title":". Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.","volume":"33","author":"Farhanghi","year":"1992","journal-title":"J Nucl Med"},{"key":"R7-8-20210202","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer.","volume":"55","author":"Coleman","year":"1987","journal-title":"Br J Cancer"},{"key":"R8-8-20210202","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/bja\/aen100","article-title":". Translational medicine: cancer pain mechanisms and management.","volume":"101","author":"Delaney","year":"2008","journal-title":"Br J Anaesth"},{"key":"R11-8-20210202","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0885-3924(98)00069-4","article-title":". Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases.","volume":"16","author":"Janjan","year":"1998","journal-title":"J Pain Symptom Manage"},{"key":"R12-8-20210202","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3959(98)00135-3","article-title":". The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials.","volume":"78","author":"Fulfaro","year":"1998","journal-title":"Pain"},{"key":"R13-8-20210202","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":". Chemotherapy with mitoxantrone, plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end point.","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"R14-8-20210202","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/104990910402100415","article-title":"Radiopharmaceuticals for palliation of painful osseous metastases.","volume":"21","author":"Smith","year":"2004","journal-title":"Am J Hosp Palliat Care"},{"key":"R15-8-20210202","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/med.20224","article-title":"Bone metastases: molecular mechanisms and novel therapeutic interventions.","volume":"32","author":"Papachristou","year":"2012","journal-title":"Med Res Rev"},{"key":"R16-8-20210202","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0305-7372(10)70013-X","article-title":". New molecular targets in bone metastases.","volume":"36","author":"Santini","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"R17-8-20210202","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bone.2005.10.003","article-title":". Regulation of SDF-1 (CXCL12) production by osteoblasts: a possible mechanism for stem cell homing.","volume":"38","author":"Jung","year":"2006","journal-title":"Bone"},{"key":"R18-8-20210202","first-page":"443","article-title":"Osteoblastic metastasis in advanced prostate cancer.","volume":"13","author":"Koutsilieris","year":"1993","journal-title":"Anticancer Res"},{"key":"R19-8-20210202","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/1040-8428(94)00122-A","article-title":"Skeletal metastases in advanced prostate cancer: cell biology and therapy.","volume":"18","author":"Koutsilieris","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"R20-8-20210202","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":". Natural history of progression after PSA elevation following radical prostatectomy.","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"R21-8-20210202","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.beem.2008.01.011","article-title":". Mechanisms of bone metastasis in prostate cancer: clinical implications.","volume":"22","author":"Msaouel","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R22-8-20210202","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":". Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-8-20210202","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.bone.2006.11.006","article-title":". DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.","volume":"40","author":"Mori","year":"2007","journal-title":"Bone"},{"key":"R24-8-20210202","first-page":"481","article-title":". Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases.","volume":"13","author":"Koutsilieris","year":"1993","journal-title":"Anticancer Res"},{"key":"R25-8-20210202","first-page":"905","article-title":"Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts.","volume":"12","author":"Koutsilieris","year":"1992","journal-title":"Anticancer Res"},{"key":"R26-8-20210202","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/13543784.10.6.1099","article-title":"Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer.","volume":"10","author":"Mitsiades","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"R27-8-20210202","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/pros.2990260506","article-title":". Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells.","volume":"26","author":"Reyes-Moreno","year":"1995","journal-title":"Prostate"},{"key":"R29-8-20210202","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00003086-198209000-00004","article-title":"Mechanisms of lytic and blastic metastatic disease of bone.","volume":"169","author":"Galasko","year":"1982","journal-title":"Clin Orthop Relat Res"},{"key":"R30-8-20210202","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1091\/mbc.e08-11-1158","article-title":". Protein tyrosine phosphatase epsilon regulates integrin-mediated podosome stability in osteoclasts by activating Src.","volume":"20","author":"Granot-Attas","year":"2009","journal-title":"Mol Biol Cell"},{"key":"R31-8-20210202","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1073\/pnas.80.9.2752","article-title":". Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.","volume":"80","author":"Sly","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R32-8-20210202","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1056\/NEJMra040952","article-title":"Osteopetrosis.","volume":"351","author":"Tolar","year":"2004","journal-title":"N Engl J Med"},{"key":"R34-8-20210202","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1172\/JCI113863","article-title":". Cytoplasmic pH regulation and chloridebicarbonate exchange in avian osteoclasts.","volume":"83","author":"Teti","year":"1989","journal-title":"J Clin Invest"},{"key":"R35-8-20210202","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/77131","article-title":". Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis.","volume":"25","author":"Frattini","year":"2000","journal-title":"Nat Genet"},{"key":"R36-8-20210202","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/hmg\/9.13.2059","article-title":". Mutations in the a3 subunit of the vacuolar H()-ATPase cause infantile malignant osteopetrosis.","volume":"9","author":"Kornak","year":"2000","journal-title":"Hum Mol Genet"},{"key":"R37-8-20210202","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/70563","article-title":". Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification.","volume":"23","author":"Li","year":"1999","journal-title":"Nat Genet"},{"key":"R38-8-20210202","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S8756-3282(99)00278-1","article-title":". The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (ococ) mutants.","volume":"26","author":"Scimeca","year":"2000","journal-title":"Bone"},{"key":"R39-8-20210202","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1126\/science.2528207","article-title":". Osteoclastic bone resorption by a polarized vacuolar proton pump.","volume":"245","author":"Blair","year":"1989","journal-title":"Science"},{"key":"R40-8-20210202","doi-asserted-by":"crossref","first-page":"C1315","DOI":"10.1152\/ajpcell.1991.260.6.C1315","article-title":". Passive chloride permeability charge coupled to H()-ATPase of avian osteoclast ruffled membrane.","volume":"260","author":"Blair","year":"1991","journal-title":"Am J Physiol"},{"key":"R41-8-20210202","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0002-9440(10)63712-1","article-title":". Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II.","volume":"164","author":"Henriksen","year":"2004","journal-title":"Am J Pathol"},{"key":"R42-8-20210202","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0002-9440(10)62269-9","article-title":". Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption.","volume":"166","author":"Karsdal","year":"2005","journal-title":"Am J Pathol"},{"key":"R43-8-20210202","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(01)00206-9","article-title":". Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man.","volume":"104","author":"Kornak","year":"2001","journal-title":"Cell"},{"key":"R44-8-20210202","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1083\/jcb.101.6.2210","article-title":". Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border.","volume":"101","author":"Baron","year":"1985","journal-title":"J Cell Biol"},{"key":"R45-8-20210202","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1083\/jcb.200209098","article-title":". Regulation of cytochrome c oxidase activity by c-Src in osteoclasts.","volume":"160","author":"Miyazaki","year":"2003","journal-title":"J Cell Biol"},{"key":"R46-8-20210202","doi-asserted-by":"crossref","first-page":"17660","DOI":"10.1074\/jbc.M311032200","article-title":". Src kinase activity is essential for osteoclast function.","volume":"279","author":"Miyazaki","year":"2004","journal-title":"J Biol Chem"},{"key":"R47-8-20210202","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3109\/s10165-006-0460-z","article-title":". The role of c-Src kinase in the regulation of osteoclast function.","volume":"16","author":"Miyazaki","year":"2006","journal-title":"Mod Rheumatol"},{"key":"R48-8-20210202","doi-asserted-by":"crossref","first-page":"12517","DOI":"10.1074\/jbc.271.21.12517","article-title":". Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification.","volume":"271","author":"Bossard","year":"1996","journal-title":"J Biol Chem"},{"key":"R49-8-20210202","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1359\/jbmr.1999.14.10.1654","article-title":". Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization.","volume":"14","author":"Gowen","year":"1999","journal-title":"J Bone Miner Res"},{"key":"R50-8-20210202","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1359\/jbmr.1999.14.11.1902","article-title":". Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation.","volume":"14","author":"Nishi","year":"1999","journal-title":"J Bone Miner Res"},{"key":"R51-8-20210202","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1073\/pnas.95.23.13453","article-title":". Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice.","volume":"95","author":"Saftig","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R52-8-20210202","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1359\/jbmr.2002.17.1.77","article-title":". The bone lining cell: its role in cleaning Howships lacunae and initiating bone formation.","volume":"17","author":"Everts","year":"2002","journal-title":"J Bone Miner Res"},{"key":"R53-8-20210202","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1001\/jama.290.18.2476","article-title":"Cancer pain.","volume":"290","author":"Bruera","year":"2003","journal-title":"JAMA"},{"key":"R54-8-20210202","first-page":"87","article-title":"The pharmacological treatment of bone pain.","volume":"7","author":"Hanks","year":"1988","journal-title":"Cancer Surv"},{"key":"R55-8-20210202","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1046\/j.1533-2500.2001.01025.x","article-title":"Cancer pain: progress since the WHO guidelines.","volume":"1","author":"Burton","year":"2001","journal-title":"Pain Pract"},{"key":"R56-8-20210202","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0304-3959(95)00017-M","article-title":". Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study.","volume":"63","author":"Zech","year":"1995","journal-title":"Pain"},{"key":"R57-8-20210202","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/030006059001800406","article-title":". Ketorolac, a new nonopioid analgesic: a double-blind trial versus pentazocine in cancer pain.","volume":"18","author":"Estape","year":"1990","journal-title":"J Int Med Res"},{"key":"R58-8-20210202","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cpt1975173277","article-title":". Double-blind study of the analgesic effect of indoprofen (K 4277).","volume":"17","author":"Fuccella","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"R59-8-20210202","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0304-3959(97)00157-7","article-title":". Double-blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain.","volume":"74","author":"Minotti","year":"1998","journal-title":"Pain"},{"key":"R60-8-20210202","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0304-3959(89)90021-3","article-title":". Double-blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain.","volume":"36","author":"Minotti","year":"1989","journal-title":"Pain"},{"key":"R61-8-20210202","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1002\/j.1552-4604.1988.tb05975.x","article-title":"A double-blind parallel evaluation of the efficacy and safety of a single dose of ketoprofen in cancer pain.","volume":"28","author":"Stambaugh","year":"1988","journal-title":"J Clin Pharmacol"},{"key":"R62-8-20210202","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/j.1552-4604.1989.tb03274.x","article-title":"A double-blind study with placebo control of intramuscular ketorolac tromethamine in the treatment of cancer pain.","volume":"29","author":"Staquet","year":"1989","journal-title":"J Clin Pharmacol"},{"key":"R63-8-20210202","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/j.1552-4604.1988.tb05977.x","article-title":"Analgesic efficacy of ketoprofen in postpartum, general surgery, and chronic cancer pain.","volume":"28","author":"Sunshine","year":"1988","journal-title":"J Clin Pharmacol"},{"key":"R64-8-20210202","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/cpt1975173284","article-title":"Indoprofen, a new analgesic and anti-inflammatory drug in cancer pain.","volume":"17","author":"Ventafridda","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"R65-8-20210202","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI119400","article-title":". Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.","volume":"99","author":"Sheng","year":"1997","journal-title":"J Clin Invest"},{"key":"R66-8-20210202","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1034\/j.1600-0714.2001.300107.x","article-title":". Specific inhibition of cyclooxygenase results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production.","volume":"30","author":"Sumitani","year":"2001","journal-title":"J Oral Pathol Med"},{"key":"R67-8-20210202","first-page":"7343","article-title":". Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2.","volume":"62","author":"Sabino","year":"2002","journal-title":"Cancer Res"},{"key":"R68-8-20210202","first-page":"775","article-title":"Blum SL, et al..","volume":"27","author":"Barkin","year":"2010","journal-title":"Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult Drugs Aging"},{"key":"R69-8-20210202","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1358\/dot.2007.43.3.1062673","article-title":"Lumiracoxib.","volume":"43","author":"Buvanendran","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"R70-8-20210202","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00000542-200501000-00022","article-title":"Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain.","volume":"102","author":"Donovan-Rodriguez","year":"2005","journal-title":"Anesthesiology"},{"key":"R71-8-20210202","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1526-4637.2000.00047.x","article-title":"Bone cancer pain: from mechanism to model to therapy.","volume":"1","author":"Honore","year":"2000","journal-title":"Pain Med"},{"key":"R72-8-20210202","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1200\/JCO.2004.08.141","article-title":". Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.","volume":"22","author":"Caraceni","year":"2004","journal-title":"J Clin Oncol"},{"key":"R73-8-20210202","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/0269216308089304","article-title":". Gabapentin for breakthrough pain due to bone metastases.","volume":"22","author":"Caraceni","year":"2008","journal-title":"Palliat Med"},{"key":"R75-8-20210202","first-page":"2","article-title":"The use of calcitonin in the treatment of metastatic bone pain.","volume":"17","author":"Kreeger","year":"1999","journal-title":"J Pain Symptom Manage"},{"key":"R76-8-20210202","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0885-3924(99)00081-0","article-title":". Continuous subcutaneous administration of high-dose salmon calcitonin in bone metastasis: pain control and beta-endorphin plasma levels.","volume":"18","author":"Mystakidou","year":"1999","journal-title":"J Pain Symptom Manage"},{"key":"R77-8-20210202","first-page":"871","article-title":". Analgesic activity of high-dose intravenous calcitonin in cancer patients with bone metastases.","volume":"16","author":"Tsavaris","year":"2006","journal-title":"Oncol Rep"},{"key":"R80-8-20210202","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","article-title":". Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.","volume":"291","author":"Viereck","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"R81-8-20210202","first-page":"163","article-title":"Effect of bisphosphonates on pain and quality of life in patients with bone metastases.","volume":"6","author":"Costa","year":"2009","journal-title":"Nat Clin Pract Oncol"},{"key":"R82-8-20210202","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review.","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"key":"R83-8-20210202","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bjp.0706628","article-title":". A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates.","volume":"147","author":"Monkkonen","year":"2006","journal-title":"Br J Pharmacol"},{"key":"R84-8-20210202","first-page":"32","article-title":"Bisphosphonates in the treatment of bone metastases.","volume":"129","author":"Finley","year":"2002","journal-title":"Semin Oncol"},{"key":"R85-8-20210202","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/bjc.1994.344","article-title":". High-dose intravenous pamidronate for metastatic bone pain.","volume":"70","author":"Purohit","year":"1994","journal-title":"Br J Cancer"},{"key":"R86-8-20210202","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"; American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"key":"R87-8-20210202","first-page":"429","article-title":", Eleftheriadis N, Sofroniadis I, et al.. Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium pamidronate.","volume":"21","author":"Pistevou-Gombaki","year":"2002","journal-title":"J Exp Clin Cancer Res"},{"key":"R88-8-20210202","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14712598.6.12.1333","article-title":". Zoledronic acid in the management of metastatic bone disease.","volume":"6","author":"Santini","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"R90-8-20210202","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10585-009-9247-x","article-title":". Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases.","volume":"26","author":"Amir","year":"2009","journal-title":"Clin Exp Metastasis"},{"key":"R91-8-20210202","first-page":"2949","article-title":". Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res"},{"key":"R92-8-20210202","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":". Zoledronic acid inhibits visceral metastases in the 4t1luc mouse breast cancer model.","volume":"10","author":"Hiraga","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R93-8-20210202","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S1470-2045(06)70927-5","article-title":"Zoledronic acid palliation in bone-metastatic breast cancer.","volume":"7","author":"Furlow","year":"2006","journal-title":"Lancet Oncol"},{"key":"R94-8-20210202","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1179\/joc.2005.17.5.555","article-title":". The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.","volume":"17","author":"Fulfaro","year":"2005","journal-title":"J Chemother"},{"key":"R95-8-20210202","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2009.06.003","article-title":". Zoledronic acid induces apoptosis and changes the trailopg ratio in breast cancer cells.","volume":"287","author":"Rachner","year":"2010","journal-title":"Cancer Lett"},{"key":"R96-8-20210202","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.cad.0000175582.01446.6f","article-title":". Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.","volume":"16","author":"Woodward","year":"2005","journal-title":"Anticancer Drugs"},{"key":"R97-8-20210202","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","article-title":". Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.","volume":"13","author":"Santini","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R98-8-20210202","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/jir.2005.25.144","article-title":". Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.","volume":"25","author":"Vincenzi","year":"2005","journal-title":"J Interferon Cytokine Res"},{"key":"R99-8-20210202","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"; Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R100-8-20210202","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":". Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase II, double-blind, randomized trialThe Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"R101-8-20210202","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":". Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"R102-8-20210202","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":". Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"R103-8-20210202","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3810\/pgm.2011.09.2470","article-title":". Management of chronic noncancer pain in depressed patients.","volume":"123","author":"Barkin","year":"2011","journal-title":"Postgrad Med"},{"key":"R104-8-20210202","doi-asserted-by":"crossref","first-page":"E343","DOI":"10.36076\/ppj.2011\/14\/E343","article-title":"Pharmacology of opioids in the treatment of chronic pain syndromes.","volume":"14","author":"Vallejo","year":"2011","journal-title":"Pain Physician"},{"key":"R105-8-20210202","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.juro.2010.10.042","article-title":"Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.","volume":"185","author":"Molina","year":"2001","journal-title":"J Urol"},{"key":"R106-8-20210202","doi-asserted-by":"crossref","first-page":"R305","DOI":"10.1677\/ERC-10-0187","article-title":"An update on androgen deprivation therapy for prostate cancer.","volume":"17","author":"Sharifi","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl 1","key":"R107-8-20210202","first-page":"S3","article-title":"Androgen deprivation therapy in the treatment of advanced prostate cancer.","volume":"9","author":"Perlmutter","year":"2007","journal-title":"Rev Urol"},{"key":"R108-8-20210202","first-page":"196","article-title":"Tyrrell CJ, et al..","volume":"4","author":"Kaisary","year":"2001","journal-title":"Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer Prostate Cancer Prostatic Dis"},{"key":"R109-8-20210202","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2007.09.002","article-title":". EAU guidelines on prostate cancer.","volume":"53","author":"Heidenreich","year":"2008","journal-title":"Eur Urol"},{"key":"R110-8-20210202","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","article-title":". EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer.","volume":"59","author":"Mottet","year":"2011","journal-title":"Eur Urol"},{"key":"R111-8-20210202","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/CMAR.S8841","article-title":"Evaluation of degarelix in the management of prostate cancer.","volume":"2","author":"Van Poppel","year":"2010","journal-title":"Cancer Manag Res"},{"key":"R112-8-20210202","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"; Prostate Cancer FoundationDepartment of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"key":"R113-8-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3816\/CGC.2010.n.003","article-title":"Changing therapeutic paradigms in castrate-resistant prostate cancer.","volume":"8","author":"Zivi","year":"2010","journal-title":"Clin Genitourin Cancer"},{"key":"R114-8-20210202","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y","article-title":"The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group.","volume":"50","author":"Tong","year":"1982","journal-title":"Cancer"},{"key":"R115-8-20210202","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0167-8140(89)90053-4","article-title":"The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief.","volume":"14","author":"Arcangeli","year":"1989","journal-title":"Radiother Oncol"},{"key":"R116-8-20210202","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0360-3016(92)90563-W","article-title":". A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases.","volume":"23","author":"Poulter","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R117-8-20210202","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0885-3924(01)00359-1","article-title":"Single fraction external beam radiation therapy in the treatment of localized metastatic bone pain. A review.","volume":"22","author":"Jeremic","year":"2001","journal-title":"J Pain Symptom Manage"},{"key":"R118-8-20210202","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0360-3016(02)04147-0","article-title":"; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dose fractionation radiotherapy trials for the palliation of painful bone metastases.","volume":"55","author":"Wu","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R119-8-20210202","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0936-6555(03)00113-4","article-title":". Palliation of metastatic bone pain: single fraction versus multifraction radiotherapya systematic review of randomized trials.","volume":"15","author":"Sze","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R120-8-20210202","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2006.09.5281","article-title":". Palliative radiotherapy trials for bone metastases: a systematic review.","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"R121-8-20210202","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrclinonc.2010.17","article-title":"Treatment of painful bone metastases.","volume":"7","author":"Rades","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"R123-8-20210202","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.semnuclmed.2009.10.003","article-title":"Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain.","volume":"40","author":"Paes","year":"2010","journal-title":"Semin Nucl Med"},{"key":"R124-8-20210202","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1148\/radiographics.9.2.2467331","article-title":". Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone.","volume":"9","author":"Robinson","year":"1989","journal-title":"Radiographics"},{"key":"R125-8-20210202","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0001-2998(05)80154-0","article-title":"Radionuclide therapy of intractable bone pain: emphasis on strontium-89.","volume":"22","author":"Robinson","year":"1992","journal-title":"Semin Nucl Med"},{"key":"R126-8-20210202","first-page":"345","article-title":"Strontium- 89 therapy for the pain of osseous metastases.","volume":"26","author":"Silberstein","year":"1985","journal-title":"J Nucl Med"},{"key":"R127-8-20210202","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s002590000315","article-title":". Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement.","volume":"27","author":"Kraeber-Bodere","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"R128-8-20210202","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(05)70206-0","article-title":"Radioisotopes for the palliation of metastatic bone cancer: a systematic review.","volume":"6","author":"Finlay","year":"2005","journal-title":"Lancet Oncol"},{"key":"R129-8-20210202","first-page":"559","article-title":"The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone.","volume":"64","author":"Friedell","year":"1950","journal-title":"Am J Roentgenol Radium Ther"},{"key":"R130-8-20210202","first-page":"10","article-title":"The treatment of painful osseous metastases with phosphorus-32-labeled phosphates.","volume":"20","author":"Silberstein","year":"1993","journal-title":"Semin Oncol"},{"key":"R131-8-20210202","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/00002512-199711050-00007","article-title":"Samarium 153Sm lexidronam.","volume":"11","author":"Lamb","year":"1997","journal-title":"Drugs Aging"},{"key":"R132-8-20210202","first-page":"83","article-title":"153-lexidronam for painful bone metastases.","volume":"39","year":"1997","journal-title":"Med Lett Drugs Ther"},{"key":"R133-8-20210202","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0001-2998(05)80156-4","article-title":"153Sm EDTMP: a potential therapy for bone cancer pain.","volume":"22","author":"Holmes","year":"1992","journal-title":"Semin Nucl Med"},{"key":"R134-8-20210202","first-page":"63","article-title":". Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.","volume":"35","author":"Bayouth","year":"1994","journal-title":"J Nucl Med"},{"key":"R135-8-20210202","first-page":"1839","article-title":". Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase III trial.","volume":"34","author":"Collins","year":"1993","journal-title":"J Nucl Med"},{"key":"R136-8-20210202","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0167-8140(97)01912-9","article-title":". Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone.","volume":"43","author":"Alberts","year":"1997","journal-title":"Radiother Oncol"},{"key":"R137-8-20210202","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cncr.22431","article-title":". Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.","volume":"109","author":"Sartor","year":"2007","journal-title":"Cancer"},{"key":"R138-8-20210202","first-page":"1346","article-title":"Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer.","volume":"10","author":"Liepe","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"R139-8-20210202","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.tvir.2007.09.003","article-title":"Image-guided palliation of painful metastases using percutaneous ablation.","volume":"10","author":"Callstrom","year":"2007","journal-title":"Tech Vasc Interv Radiol"},{"key":"R140-8-20210202","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2214\/ajr.175.5.1751263","article-title":". Radiofrequency ablation of spinal tumors: temperature distribution in the spinal canal.","volume":"175","author":"Dupuy","year":"2000","journal-title":"AJR Am J Roentgenal"},{"key":"R141-8-20210202","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2214\/ajr.177.4.1770777","article-title":". Radiofrequency thermal ablation: computer analysis of the size of the thermal injury created by overlapping ablations.","volume":"177","author":"Dodd","year":"2001","journal-title":"AJR Am J Roentgenal"},{"key":"R142-8-20210202","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.suponc.2011.01.001","article-title":". Percutaneous vertebral augmentation in metastatic disease: state of the art.","volume":"9","author":"Tancioni","year":"2011","journal-title":"J Support Oncol"},{"key":"R143-8-20210202","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1259\/bjr\/10254271","article-title":"Percutaneous vertebroplasty: indications, contraindications, and technique.","volume":"76","author":"Peh","year":"2003","journal-title":"Br J Radiol"},{"key":"R144-8-20210202","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1148\/radiol.2231010234","article-title":"Percutaneous vertebroplasty for severe osteoporotic vertebral body compression fractures.","volume":"223","author":"Peh","year":"2002","journal-title":"Radiology"},{"key":"R145-8-20210202","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/annonc\/mdq605","article-title":". Pain management in spinal metastases: the role of percutaneous vertebral augmentation.","volume":"22","author":"Kassamali","year":"2011","journal-title":"Ann Oncol"},{"key":"R146-8-20210202","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.ejca.2009.01.021","article-title":". The efficacy of percutaneous vertebroplasty for vertebral metastases associated with solid malignancies.","volume":"45","author":"Lee","year":"2009","journal-title":"Eur J Cancer"},{"key":"R147-8-20210202","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1148\/radiol.09081698","article-title":"Kocheida el M, Lehmann P, et al.. Percutaneous vertebroplasty for pain management in malignant fractures of the spine with epidural involvement.","volume":"254","author":"Saliou","year":"2010","journal-title":"Radiology"},{"key":"R148-8-20210202","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s11604-010-0542-x","article-title":". Therapeutic effects of percutaneous vertebroplasty for vertebral metastases.","volume":"29","author":"Mikami","year":"2001","journal-title":"Jpn J Radiol"},{"key":"R149-8-20210202","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.crad.2010.09.011","article-title":". Safety and efficacy of percutaneous vertebroplasty in malignancy: a systematic review.","volume":"66","author":"Chew","year":"2011","journal-title":"Clin Radiol"},{"key":"R150-8-20210202","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jocn.2010.09.021","article-title":". Kyphoplasty for the treatment of malignant vertebral compression fractures caused by metastases.","volume":"18","author":"Qian","year":"2011","journal-title":"J Clin Neurosci"},{"key":"R151-8-20210202","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11916-008-0043-0","article-title":"Intrathecal analgesia for refractory cancer pain.","volume":"12","author":"Newsome","year":"2008","journal-title":"Curr Pain Headache Rep"},{"key":"R152-8-20210202","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.36076\/ppj.2008\/11\/S89","article-title":". Intrathecal drug delivery.","volume":"11","author":"Smith","year":"2008","journal-title":"Pain Physician"},{"key":"R153-8-20210202","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.2002.02.118","article-title":"; Implantable Drug Delivery Systems Study Group. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.","volume":"20","author":"Smith","year":"2002","journal-title":"J Clin Oncol"},{"key":"R154-8-20210202","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1525-1403.2007.00128.x","article-title":". Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel.","volume":"10","author":"Deer","year":"2007","journal-title":"Neuromodulation"},{"key":"R155-8-20210202","doi-asserted-by":"crossref","first-page":"E283","DOI":"10.36076\/ppj.2011\/14\/E283","article-title":". A comprehensive evidence based consensus on patient selection, trialing, implantation, and management of intrathecal drug delivery systems in the treatment of pain caused by cancer pain and at the end of life: report of an expert panel.","volume":"14","author":"Deer","year":"2011","journal-title":"Pain Physician"},{"key":"R156-8-20210202","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1155\/2009\/538675","article-title":". Intrathecal infusions for intractable cancer pain: a qualitative study of the impact on a case series of patients and caregivers.","volume":"14","author":"Hawley","year":"2009","journal-title":"Pain Res Manag"},{"key":"R157-8-20210202","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","article-title":". Activated T cell regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"R158-8-20210202","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":". Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"R159-8-20210202","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/74977","article-title":"Bone cancer gain without the pain.","volume":"6","author":"Thompson","year":"2000","journal-title":"Nat Med"},{"key":"R160-8-20210202","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":". A phase I study of amgn-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"R161-8-20210202","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/ar2171","article-title":"Clinical development of anti-RANKL therapy.","volume":"9","author":"Schwarz","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"R162-8-20210202","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":". Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"R163-8-20210202","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":". Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"R164-8-20210202","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.bone.2010.01.078","article-title":". Results of a prospective, randomized, double-blind, double-dummy, Phase 3 study comparing denosumab with zoledronic acid for the treatment of breast cancer patients with bone metastases.","volume":"46","author":"Body","year":"2010","journal-title":"Bone"},{"key":"R167-8-20210202","doi-asserted-by":"crossref","first-page":"32347","DOI":"10.1074\/jbc.273.48.32347","article-title":". The collagenolytic activity of cathepsin K is unique among mammalian proteinases.","volume":"273","author":"Garnero","year":"1998","journal-title":"J Biol Chem"},{"key":"R168-8-20210202","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1074\/jbc.M805280200","article-title":". Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption.","volume":"284","author":"Wilson","year":"2009","journal-title":"J Biol Chem"},{"key":"R169-8-20210202","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1349-7006.2009.01294.x","article-title":"Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases.","volume":"100","author":"Kawatani","year":"2009","journal-title":"Cancer Sci"},{"key":"R170-8-20210202","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","article-title":". A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.","volume":"67","author":"Le Gall","year":"2007","journal-title":"Cancer Res"},{"key":"R171-8-20210202","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ncprheum0977","article-title":"Potential new drug targets for osteoporosis.","volume":"5","author":"Deal","year":"2009","journal-title":"Nat Clin Pract Rheumatol"},{"key":"R172-8-20210202","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/clpt.2009.60","article-title":". Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled Phase I studies.","volume":"86","author":"Stoch","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R174-8-20210202","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1359\/jbmr.1997.12.9.1396","article-title":". Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.","volume":"12","author":"Votta","year":"1997","journal-title":"J Bone Miner Res"},{"key":"R175-8-20210202","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/BOR.0b013e32832cbc2a","article-title":"Future therapeutic targets in osteoporosis.","volume":"21","author":"Deal","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"R176-8-20210202","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nrc1366","article-title":"A renaissance for SRC.","volume":"4","author":"Yeatman","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R177-8-20210202","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2009-0009","article-title":"The role of Src in solid tumors.","volume":"14","author":"Wheeler","year":"2009","journal-title":"Oncologist"},{"key":"R178-8-20210202","doi-asserted-by":"crossref","first-page":"7868","DOI":"10.1038\/sj.onc.1208079","article-title":"The interplay between Src family kinases and receptor tyrosine kinases.","volume":"23","author":"Bromann","year":"2004","journal-title":"Oncogene"},{"key":"R179-8-20210202","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2009.05.017","article-title":". Latent bone metastasis in breast cancer tied to Src-dependent survival signals.","volume":"16","author":"Zhang","year":"2009","journal-title":"Cancer Cell"},{"key":"R180-8-20210202","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0092-8674(91)90499-O","article-title":". Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice.","volume":"64","author":"Soriano","year":"1991","journal-title":"Cell"},{"key":"R181-8-20210202","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1172\/JCI119790","article-title":". Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts.","volume":"100","author":"Insogna","year":"1997","journal-title":"J Clin Invest"},{"key":"R182-8-20210202","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1097-2765(00)80232-4","article-title":". TRANCE, a TNF family member, activates Akt[Fraction Slash]PKB through a signaling complex involving TRAF6 and c-Src.","volume":"4","author":"Wong","year":"1999","journal-title":"Mol Cell"},{"key":"R183-8-20210202","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1101\/gad.11.21.2835","article-title":". Rescue of osteoclast function by transgenic expression of kinase-deficient src in src-- mutant mice.","volume":"11","author":"Schwartzberg","year":"1997","journal-title":"Genes Dev"},{"key":"R184-8-20210202","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1073\/pnas.90.10.4485","article-title":". Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts.","volume":"90","author":"Lowe","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R185-8-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.23998","article-title":"Targeting Src signaling in metastatic bone disease.","volume":"124","author":"Araujo","year":"2009","journal-title":"Int J Cancer"},{"key":"R186-8-20210202","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/annonc\/mdn291","article-title":"Targeting Src in breast cancer.","volume":"19","author":"Finn","year":"2008","journal-title":"Ann Oncol"},{"key":"R187-8-20210202","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-006-9463-x","article-title":". Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-typetriple-negative breast cancer cell lines growing in vitro.","volume":"105","author":"Finn","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"R188-8-20210202","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/jpet.106.102004","article-title":"Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy.","volume":"318","author":"Rucci","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"R189-8-20210202","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/187152008783961905","article-title":"Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases.","volume":"8","author":"Rucci","year":"2008","journal-title":"Anticancer Agents Med Chem"},{"key":"R191-8-20210202","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/01.ju.0000096372.07687.86","article-title":"Endothelin inhibition: novel therapy for prostate cancer.","volume":"170","author":"Nelson","year":"2003","journal-title":"J Urol"},{"key":"R192-8-20210202","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ejca.2008.03.001","article-title":"Challenges in cancer pain managementbone pain.","volume":"44","author":"Colvin","year":"2008","journal-title":"Eur J Cancer"},{"key":"R193-8-20210202","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00005344-200000002-00002","article-title":"The endothelin family: an overview.","volume":"35","author":"Masaki","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"R194-8-20210202","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1210\/me.2006-0346","article-title":". Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.","volume":"12","author":"Clines","year":"2007","journal-title":"Mol Endocrinol"},{"key":"R195-8-20210202","first-page":"223","article-title":"Massive amounts of immunoreactive endothelin in human seminal fluid.","volume":"74","author":"Casey","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"R196-8-20210202","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/S0022-5347(01)64776-1","article-title":". Gene expression and autoradiographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate.","volume":"157","author":"Prayer-Galetti","year":"1997","journal-title":"J Urol"},{"key":"R197-8-20210202","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm0995-944","article-title":". Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate.","volume":"1","author":"Nelson","year":"1995","journal-title":"Nat Med"},{"key":"R198-8-20210202","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","article-title":". Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.","volume":"21","author":"Carducci","year":"2003","journal-title":"J Clin Oncol"},{"key":"R199-8-20210202","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00345-004-0478-9","article-title":"Endothelin receptor antagonists.","volume":"23","author":"Nelson","year":"2005","journal-title":"World J Urol"},{"key":"R200-8-20210202","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/01.ju.0000042162.08938.27","article-title":". Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.","volume":"169","author":"Nelson","year":"2003","journal-title":"J Urol"},{"key":"R201-8-20210202","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/cncr.22996","article-title":"; Atrasentan Phase III Study Group Institutions. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.","volume":"110","author":"Carducci","year":"2007","journal-title":"Cancer"},{"key":"R202-8-20210202","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.eururo.2008.11.002","article-title":". Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.","volume":"55","author":"James","year":"2009","journal-title":"Eur Urol"},{"key":"R203-8-20210202","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1464-410X.2010.09638.x","article-title":". Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.","volume":"106","author":"James","year":"2010","journal-title":"BJU Int"},{"key":"R204-8-20210202","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10555-006-9019-x","article-title":"The pivotal role of CXCL12 (SDF-1)CXCR4 axis in bone metastasis.","volume":"25","author":"Wang","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"R205-8-20210202","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1158\/0008-5472.CAN-03-3958","article-title":". Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.","volume":"64","author":"Liang","year":"2004","journal-title":"Cancer Res"},{"key":"R206-8-20210202","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1359\/JBMR.041109","article-title":". Skeletal localization and neutralization of the SDF-1(CXCL12)CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.","volume":"20","author":"Sun","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R207-8-20210202","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1158\/0008-5472.CAN-04-1844","article-title":". CXCR4 regulates growth of both primary and metastatic breast cancer.","volume":"64","author":"Smith","year":"2004","journal-title":"Cancer Res"},{"key":"R208-8-20210202","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jss.2008.06.044","article-title":". A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer.","volume":"155","author":"Huang","year":"2009","journal-title":"J Surg Res"},{"key":"R209-8-20210202","first-page":"761","article-title":". Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone.","volume":"21","author":"Richert","year":"2009","journal-title":"Oncol Rep"},{"key":"R210-8-20210202","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bbi.2010.12.014","article-title":". CXCR4 signaling mediates morphine-induced tactile hyperalgesia.","volume":"25","author":"Wilson","year":"2011","journal-title":"Brain Behav Immun"},{"key":"R211-8-20210202","doi-asserted-by":"crossref","first-page":"6305s","DOI":"10.1158\/1078-0432.CCR-06-1157","article-title":"Future treatment of bone metastases.","volume":"12","author":"Lipton","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R212-8-20210202","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nrn1914","article-title":"Cancer pain and its impact on diagnosis, survival and quality of life.","volume":"7","author":"Mantyh","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"R213-8-20210202","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00520-008-0487-0","article-title":". Metastatic bone pain: treatment options with an emphasis on bisphosphonates.","volume":"16","author":"von Moos","year":"2008","journal-title":"Support Care Cancer"},{"key":"R215-8-20210202","first-page":"427","article-title":"Osteoclasts: what do they do and how do they do it Am J Pathol.","volume":"170","author":"Teitelbaum","year":"2007","journal-title":""},{"key":"R216-8-20210202","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35093019","article-title":"Molecular mechanisms of nociception.","volume":"413","author":"Julius","year":"2001","journal-title":"Nature"},{"key":"R217-8-20210202","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.neuroscience.2007.05.049","article-title":". Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons.","volume":"148","author":"Niiyama","year":"2007","journal-title":"Neuroscience"},{"key":"R218-8-20210202","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1523\/JNEUROSCI.3815-04.2005","article-title":". Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain.","volume":"25","author":"Ghilardi","year":"2005","journal-title":"J Neurosci"},{"key":"R219-8-20210202","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/bja\/aen347","article-title":". SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine on bone cancer pain.","volume":"102","author":"Niiyama","year":"2009","journal-title":"Br J Anaesth"},{"key":"R220-8-20210202","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/ALN.0b013e3181a51e0d","article-title":". Reduction of bone cancer pain by activation of spinal cannabinoid receptor 1 and its expression in the superficial dorsal horn of the spinal cord in a murine model of bone cancer pain.","volume":"111","author":"Furuse","year":"2009","journal-title":"Anesthesiology"},{"key":"R221-8-20210202","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1749-6632.2009.05429.x","article-title":". Bone cancer pain.","volume":"1198","author":"Jimenez-Andrade","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"R222-8-20210202","doi-asserted-by":"crossref","first-page":"9426","DOI":"10.1158\/0008-5472.CAN-05-0826","article-title":". A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone.","volume":"65","author":"Halvorson","year":"2005","journal-title":"Cancer Res"},{"key":"R223-8-20210202","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.pain.2005.02.022","article-title":". Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization.","volume":"115","author":"Sevcik","year":"2005","journal-title":"Pain"},{"key":"R224-8-20210202","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/14728214.2011.588600","article-title":". New targets, new drugs for metastatic bone pain: a new philosophy.","volume":"16","author":"Pantano","year":"2011","journal-title":"Expert Opin Emerg Drugs"},{"key":"R225-8-20210202","doi-asserted-by":"crossref","first-page":"14649","DOI":"10.1523\/JNEUROSCI.3300-10.2010","article-title":". Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain.","volume":"30","author":"Jimenez-Andrade","year":"2010","journal-title":"J Neurosci"},{"key":"R226-8-20210202","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1744-8069-6-87","article-title":". Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain.","volume":"6","author":"Ghilardi","year":"2010","journal-title":"Mol Pain"},{"key":"R227-8-20210202","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1093\/brain\/awq194","article-title":". Systemic blockade of P2X3 and P2X23 receptors attenuates bone cancer pain behaviour in rats.","volume":"133","author":"Kaan","year":"2010","journal-title":"Brain"},{"key":"R229-8-20210202","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1073\/pnas.0409888102","article-title":". CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids.","volume":"102","author":"Ibrahim","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R230-8-20210202","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pain.2005.12.018","article-title":". CB2 cannabinoid receptor mediation of antinociception.","volume":"122","author":"Ibrahim","year":"2006","journal-title":"Pain"},{"key":"R231-8-20210202","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2174\/092986707780363023","article-title":"The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists.","volume":"14","author":"Whiteside","year":"2007","journal-title":"Curr Med Chem"},{"key":"R232-8-20210202","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1073\/pnas.0504187103","article-title":". Peripheral cannabinoid receptor, CB2, regulates bone mass.","volume":"103","author":"Ofek","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R233-8-20210202","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1093\/hmg\/ddi370","article-title":". Cannabinoid receptor type 2 gene is associated with human osteoporosis.","volume":"14","author":"Karsak","year":"2005","journal-title":"Hum Mol Genet"},{"key":"R234-8-20210202","doi-asserted-by":"crossref","first-page":"H2210","DOI":"10.1152\/ajpheart.00688.2007","article-title":". CB2 receptor stimulation attenuates TNF-alpha-induced human epithelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion.","volume":"293","author":"Rajesh","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R235-8-20210202","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1189\/jlb.0303101","article-title":". The cannabinoid system and immune modulation.","volume":"74","author":"Klein","year":"2003","journal-title":"J Leukoc Biol"},{"key":"R236-8-20210202","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2174\/138161206777947425","article-title":"Cannabinoids, immune system and cytokine network.","volume":"12","author":"Massi","year":"2006","journal-title":"Curr Pharm Des"},{"key":"R237-8-20210202","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/ALN.0b013e318167af74","article-title":"Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury.","volume":"108","author":"Romero-Sandoval","year":"2008","journal-title":"Anesthesiology"},{"key":"R238-8-20210202","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.lfs.2010.02.014","article-title":". A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.","volume":"86","author":"Lozano-Ondoua","year":"2010","journal-title":"Life Sci"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e3182456dff","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T18:36:53Z","timestamp":1644172613000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201403000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":222,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3182456dff","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}